Nicole Tafuri, APRN
Primary Care · Cincinnati, OHNPI 1659941912
Payments from drug & device makers
Across 82 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$315
- Lilly USA, LLC$190
- Pfizer$169
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$154
- Novartis$110
- Johnson & Johnson$100
- plus $531 from 18 others
What the payments were for
- Food & beverage$1,46994%
- Education$1006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $315 |
| Lilly USA, LLC | 13 | $190 |
| Pfizer | 9 | $169 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $154 |
| Novartis | 7 | $110 |
| Johnson & Johnson | 1 | $100 |
| Amgen | 2 | $90 |
| Novo Nordisk | 4 | $57 |
| Gilead | 2 | $55 |
| Exact Sciences | 3 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| AstraZeneca(2 entities) | 2 | $27 |
| Bayer | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $17 |
| Vivus LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| GSK | 1 | $14 |
How this compares
$1,569 in reported general payments places this provider in the 75th percentile of 321 primary care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 80 | $113,805 |
| EliquisApixaban | 97 | $76,029 |
| OzempicSemaglutide | 55 | $71,567 |
| TrulicityDulaglutide | 39 | $60,427 |
| XareltoRivaroxaban | 38 | $34,483 |
| FarxigaDapagliflozin Propanediol | 30 | $32,679 |
| JanuviaSitagliptin Phosphate | 26 | $31,284 |
| MounjaroTirzepatide | 21 | $24,125 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $21,279 |
| Spiriva RespimatTiotropium Bromide | 25 | $12,744 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $10,894 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $8,269 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $8,033 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $7,649 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $7,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $190 | $84,55260 claims |
| PfizerEliquis | $169 | $76,02997 claims |
| Novo NordiskOzempic | $57 | $71,56755 claims |
| AstraZenecaFarxiga, Symbicort | $27 | $40,94855 claims |
| Johnson & JohnsonXarelto | $100 | $34,48338 claims |
| MerckJanuvia | $17 | $31,28426 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $14 | $28,92844 claims |
| AbbVieSynthroid | $315 | $2,95650 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 321 primary care providers in Ohio.
Other primary care in Cincinnati
- Ashley SheaCincinnati$4K
- Suzanne KahleCincinnati$4K
- Tiffany EscobarCincinnati$3K
- Adine EdwardsSpringfield$14K
- Kelly McKenna TaulbeeHamilton$12K
- Lindsay ChappellFairlawn$11K
- Laura HolligerNorth Canton$10K
- Caitlyn FrantzDayton$10K
- Brandy RichardsCleveland$8K
- Regan HeagenFindlay$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.